Sarcomas of the female genital tract are rare tumors. They are described to be associated with a poor prognosis when compared with gynecogical carcinoma. The aim of this study was to report incidence patterns and survival rates for gynecological sarcoma (GS) in Germany.
Clinical data and survival rates for patients with GS diagnosed in Germany between 2009 and 2013 were extracted from the German national center for population-based cancer registry data. Incidence patterns and 5-year relative survival rates were calculated.
A total of 1066 GSs were included in our analysis during a 5-year time span. The uterus was the most common site, with 87.9% of all cases. The annual age-standardized incidence rate (old European standard) was 8.7 per 1 million women for all GSs. The median age at diagnosis was 59 years. The prognosis ranged according to site, stage, and subtype, for example, from a 5-year relative survival of 53.0% (uterine leiomyosarcoma) if confined to the pelvis, to a very good 5-year relative survival of 97.2% (endometrial stromal sarcoma).
Despite the rareness of GS, the size of the data set allows for a differentiation of subtypes according to morphology and site of origin. Clinically relevant differences in incidence and prognosis between subgroups were observed.
*Department of Gynecology, European Competence Centre for Ovarian Cancer and Rare Tumors (EKZE), Charite—University Medicine of Berlin; and †Department of Epidemiology and Health Monitoring, German Centre for Cancer Registry Data (ZfKD), Robert Koch-Institute, Berlin, Germany.
Address correspondence and reprint requests to Klaus Pietzner, MD, Department of Gynecology, European Competence Centre for Ovarian Cancer and Rare Tumors (EKZE), Charite—University Medicine of Berlin, Augustenburger Platz 1, 13353 Berlin, Germany. E-mail: firstname.lastname@example.org.
Data from this article were presented online at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago.
No part of this article is published or intended for publication elsewhere.
The authors declare no conflicts of interest.
Received May 8, 2017
Received in revised form August 7, 2017
Accepted August 9, 2017